Search Results
| Year | ID | Type | Category | Title | Authors |
|---|
| 2019 | CSR12 | Poster | Case Reports/Case Series |
The Nelson Mog-Ab Unicorns – an ‘unfairy’ Tale |
Stephanie A Rout, MNS, BN, RN, Neurology Department, Nelson Marlborough District Health Board, Nelson, New Zealand |
| 2019 | CSR13 | Poster | Case Reports/Case Series |
A Case to Screen for Teriflunomide-Associated Neuropathy |
Christopher M Perrone, MD and Dina Jacobs, MD, Neurology, University of Pennsylvania, Philadelphia, PA |
| 2019 | CSR14 | Poster | Case Reports/Case Series |
Cervical Spondylotic Myelopathy Mimicking Transverse Myelitis: Case Series and Literature Review of Distinguishing Clinical and Radiological Features |
Yujie Wang, MD and Scott D. Newsome, DO, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD |
| 2019 | CSR15 | Poster | Case Reports/Case Series |
Remote Intracranial Granulomas As a Rare Presenting Feature of ANCA-Negative Granulomatosis with Polyangiitis Mimicking Tumefactive Multiple Sclerosis |
Swathy Chandrashekhar, MD, Christopher W Hollen, MD, Mausaminben Hathidara, MD and Nidhiben Anadani, MD, Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, OK |
| 2019 | CSR16 | Poster | Case Reports/Case Series |
Illustrating Challenges in Determining When to Discontinue Disease Modifying Therapies |
Ye Hu, MD, Michael Persenaire, MD, Gloria von Geldern, MD and Annette Wundes, MD, University of Washington, Seattle, WA |
| 2019 | CSR17 | Poster | Case Reports/Case Series |
Concurrence of Relapsing Remitting Multiple Sclerosis and Glioma over a Prolonged Period |
Chantal Kahovec, RN(NP) and Dr. Michael C Levin, M.D., FRCPC, FAAN, FANA, Saskatoon MS Clinic, Saskatchewan Health Authority, Saskatoon, SK, Canada |
| 2019 | CSR18 | Poster | Case Reports/Case Series |
Novel Clinical Observations in Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disorders |
Allison N Block, DO1, Michelle Maynard, PharmD, BCPS2 and Ahmed Z Obeidat, MD, PhD1, (1)Neurology, Medical College of Wisconsin, Milwaukee, WI, (2)Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI |
| 2019 | CSR19 | Poster | Case Reports/Case Series |
Poor Seroprotection Rate to Hepatitis B Immunization with Accelerated Regimen in Cohort of MS Patients |
Ye Hu, MD, Michael Persenaire, MD, Gloria von Geldern, MD, Pamela S Davies, MS, ARNP, FAANP, Deb Cramer, RN, BSN, MSCN, Deborah K Gallaro, R.Ph., MSCS, Melissa F Kennedy, RN and Annette Wundes, MD, University of Washington, Seattle, WA |
| 2019 | CSR20 | Poster | Case Reports/Case Series |
Multiple Sclerosis, Relapses, Disease Modifying Therapies: Critical Decisions and Considering “When it’s More Than Just MS” |
Barbara Bumstead, MS, ANCP, MSCN, Jared Srinivasan, BA, Myassar Zarif, MD, Lori Fafard, RN, BSN, CNRN, MSCN, CCRP, Marijean Buhse, PhD, NP, RN, MSCN and Mark Gudesblatt, MD, South Shore Neurologic Associates, Patchogue, NY |
| 2019 | CSR21 | Poster | Case Reports/Case Series |
Pattern of Disease Progression in Multiple Sclerosis Patients with Positive Concomitant Antiphospholipid Antibodies |
Nicole Khezri, BA1, Caila B Vaughn, PhD, MPH2, Bianca Weinstock-Guttman, MD2 and Svetlana Eckert, MD1, (1)Jacobs School of Medicine and Biomedical Sciences at the University of Buffalo, Buffalo, NY, (2)Neurology, University at Buffalo, Buffalo, NY |
| 2019 | CSR22 | Poster | Case Reports/Case Series |
Mumps Myelitis with Relapse |
Brooke L Guerrero, MD, Neurology-Multiple Sclerosis, Cedars-Sinai Medical Center, Los Angeles, CA |
| 2019 | CSR23 | Poster | Case Reports/Case Series |
Observations of an Academic Multiple Sclerosis Clinic Regarding Changes in Multiple Sclerosis Disease Course Following the Onset of Seizures |
F Stephen Benesh, MD and John R Rinker, MD, Neurology, University of Alabama at Birmingham, Birmingham, AL |
| 2019 | DXT01 | Poster | Disease Modifying Therapy |
Durability of Neda-3 Status in Patients with Relapsing Multiple Sclerosis Receiving Cladribine Tablets: Clarity Extension |
Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, Queen Mary University of London, London, United Kingdom, Birgit Keller, Diplom, Merck KGaA, Darmstadt, Germany and Dominic Jack, PhD, Merck Serono Ltd, Middlesex, United Kingdom |
| 2019 | DXT02 | Poster | Disease Modifying Therapy |
Magnims Score-Assessed Disease Activity Predicts Long-Term Activity-Free Status and Disability Progression in Subcutaneous Interferon beta-1a-Treated Patients |
Maria Pia Sormani, PhD, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, Julie Aldridge, MS, Research & Development Institute, EMD Serono, Inc., Billerica, MA, Kurt Marhardt, MD, Merck GmbH, Vienna, Austria and Nicola De Stefano, MD, Department of Medicine, Surgery, and Neurosciences, University of Siena, Siena, Italy |
| 2019 | DXT03 | Poster | Disease Modifying Therapy |
Evaluating Early Launch Siponimod Uptake for the Treatment of Secondary Progressive Multiple Sclerosis Against Prelaunch Expectations Among U.S. Neurologists |
Virginia R Schobel, MSc, Neurology Market Intelligence, Spherix Global Insights, Exton, PA and Jennifer Robinson, BS, President, Spherix Global Insights, Exton, PA |
| 2019 | DXT04 | Poster | Disease Modifying Therapy |
First-Line Therapy Selection: How Do Multiple Sclerosis Patients Influence Adoption of U.S. Neurologists’ High-Efficacy Therapy Recommendations? |
Virginia R Schobel, MSc, Neurology Market Intelligence, Spherix Global Insights, Exton, PA and Jennifer Robinson, BS, President, Spherix Global Insights, Exton, PA |
| 2019 | DXT05 | Poster | Disease Modifying Therapy |
Alemtuzumab Improves Clinical and MRI Outcomes in RRMS Patients Across Age Groups: CARE-MS I and II 8-Year Follow-up |
Ann D Bass, MD1, Rafael Arroyo, MD2, Aaron Boster, MD3, Alexey N Boyko, MD4, Sara Eichau, MD, PhD5, Donna Graves, MD6, Mary Margaret Hillstrand, DNP, ANP7, Carolina Ionete, MD, PhD8, Volker Limmroth, MD, PhD9, Carlos Navas, MD10, Daniel Pelletier, MD11, Carlo Pozzilli, MD12, Jennifer Ravenscroft, PA-C, MSCS13, Livia Sousa, MD14, Mar Tintore, MD, PhD15, Bernard MJ Uitdehaag, MD, PhD16, Darren P Baker, PhD17, Nadia Daizadeh, PhD17, Zia Choudhry, MD, PhD, MBA17, David Rog, MD18 and on behalf of the CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators, (1)Neurology Center of San Antonio, San Antonio, TX, (2)Hospital Universitario Quirónsalud Madrid, Madrid, Spain, (3)OhioHealth Multiple Sclerosis Center, Columbus, OH, (4)Pirogov Russian National Research University & Demyelinating Diseases Center, Usupov Hospital, Moscow, Russia, (5)Hospital Universitario Virgen Macarena, Seville, Spain, (6)Neuroscience Institute-Neurology, Atrium Health, Charlotte, NC, (7)Neurological Services, Anchorage, AK, (8)Department of Neurology, University of Massachusetts Memorial Medical Center, Worcester, MA, (9)Klinik fur Neurologie und Palliativmedizin, Cologne, Germany, (10)Clinica Universitaria Colombia, Bogota, Colombia, (11)Keck School of Medicine of University of Southern California, Los Angeles, CA, (12)University of Rome, Rome, Italy, (13)Kansas City MS Center, Overland Park, KS, (14)Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, (15)University Hospital Vall d’Hebron, Barcelona, Spain, (16)VU University Medical Center, Amsterdam, Netherlands, (17)Sanofi, Cambridge, MA, (18)Salford Royal NHS Foundation Trust, Salford, United Kingdom |
| 2019 | DXT06 | Poster | Disease Modifying Therapy |
Evaluation of the Safety and Efficacy of Alemtuzumab in Relapsing Remitting Multiple Sclerosis |
Julie Kidd, PharmD, MPH, BCPS, CPP, Specialty Pharmacy, Novant Health, Winston-Salem, NC, Sandrine Tchinda, PharmD, Novant Health Prince William Medical Center, Manassas, VA, Matthew Carraro, MD, Center for Multiple Sclerosis, Novant Health, Charlotte, NC and Nora Schuette, PA, Center for Multiple Sclerosis, Novant Health, Charlotte, NC |
| 2019 | DXT07 | Poster | Disease Modifying Therapy |
Assessing Teriflunomide Treatment Satisfaction in the Real-World Teri-PRO and Taurus-MS I Studies |
Bhupendra Khatri, MD1, David Rog, MD2, Andrew Chan, MD3, Jose Meca-Lallana, MD4, Patricia K Coyle, MD5, Keith Edwards, MD6, Boris A Kallmann, MD7, Steven Cavalier, MD8, Jennifer S Kullmann, MD9, Elizabeth M Poole, PhD8 and Thorsten Rosenkranz, MD, on behalf of the Teri-PRO and TAURUS-MS I investigators10, (1)Center for Neurological Disorders, Milwaukee, WI, (2)Salford Royal NHS Foundation Trust, Salford, United Kingdom, (3)Ambulantes Neurozentrum, Inselspital, Bern, Switzerland, (4)Unidad de Esclerosis Multiple en Hospital Virgen de la Arrixaca, El Palmar, Spain, (5)Stony Brook University, Stony Brook, NY, (6)MS Center of Northeastern New York, Latham, NY, (7)MS Center Bamberg, Bamberg, Germany, (8)Sanofi, Cambridge, MA, (9)Sanofi, Neu-Isenberg, Germany, (10)Asklepios Klinik St Georg, Hamburg, Germany |
| 2019 | DXT08 | Poster | Disease Modifying Therapy |
Disability Improvement in Each Functional System in Alemtuzumab-Treated RRMS Patients Over 6 Years Regardless of Baseline EDSS Score |
Samuel F Hunter, MD, PhD1, Rany A Aburashed, DO2, Raed Alroughani, MD3, Andrew Chan, MD4, Dominique Dive, MD, PhD5, Sara Eichau, MD, PhD6, Daniel Kantor, MD7, Ho Jin Kim, MD8, Jan Lycke, MD9, Richard AL Macdonell, MD10, Carlo Pozzilli, MD11, Thomas F Scott, MD12, Basil Sharrack, MD, PhD13, Heinz Wiendl, MD14, Luke Chung, MD, MPH15, Nadia Daizadeh, PhD15, Patrick Vermersch, PhD16 and on behalf of the CARE-MS II, CAMMS03409, and TOPAZ Investigators, (1)Advanced Neurosciences Institute, Franklin, TN, (2)Institute for Neurosciences and Multiple Sclerosis, Owosso, MI, (3)Amiri Hospital, Sharq, Kuwait, (4)Ambulantes Neurozentrum, Inselspital, Bern, Switzerland, (5)University Hospital Centre of Liège, Liège, Belgium, (6)Hospital Universitario Virgen Macarena, Seville, Spain, (7)Florida Atlantic University, Boca Raton, FL, (8)Research Institute and Hospital of National Cancer Center, Goyang, Korea, Republic of (South), (9)Sahlgrenska University Hospital, Gothenburg, Sweden, (10)Austin Health and Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia, (11)University of Rome, Rome, Italy, (12)Allegheny General Hospital, Pittsburgh, PA, (13)Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, (14)University of Munster, Munster, Germany, (15)Sanofi, Cambridge, MA, (16)University of Lille, Lille, France |
| 2019 | DXT09 | Poster | Disease Modifying Therapy |
Initial User Testing of Option Grid Decision Aids for Multiple Sclerosis Disease Modifying Therapies |
Hasna Hakim, DNP, RN, MSN, CCRN, MPHc, Nursing, Dartmouth, Hanover, NH, Pamela K Newland, RN, PhD, CMSRN, 4483 Duncan Avenue, Goldfarb School of Nursing at Barnes Jewish College, St Louis, MO and Brant J. Oliver, PhD, MS, MPH, APRN-BC, Geisel School of Medicine, Hanover, NH |
| 2019 | DXT10 | Poster | Disease Modifying Therapy |
Improved Outcomes With Alemtuzumab Following Switch From SC IFNB-1a: 6-Year Follow-up of CARE-MS II Patients With Active RRMS (TOPAZ Study) |
Carolina Ionete, MD, PhD1, Maria Pia Amato, MD2, Michael Barnett, PhD, MD3, Aaron Boster, MD4, Dominique Dive, MD, PhD5, Donna Graves, MD6, William David Honeycutt, MD7, Christopher LaGanke, MD8, Richard AL Macdonell, MD9, Xavier Montalban, MD, PhD10,11, Kunio Nakamura, PhD12, Celia Oreja-Guevara, MD13, David Rog, MD14, Bernard MJ Uitdehaag, MD, PhD15, Luke Chung, MD, MPH16, Nadia Daizadeh, PhD16, Salman Afsar, MD16, Anthony Traboulsee, MD17 and on behalf of the CARE-MS II, CAMMS03409, and TOPAZ Investigators, (1)Department of Neurology, University of Massachusetts Memorial Medical Center, Worcester, MA, (2)University of Florence, Florence, Italy, (3)University of Sydney, Sydney, NSW, Australia, (4)OhioHealth Multiple Sclerosis Center, Columbus, OH, (5)University Hospital Centre of Liège, Liège, Belgium, (6)Neuroscience Institute-Neurology, Atrium Health, Charlotte, NC, (7)Neurology Associates, Maitland, FL, (8)North Central Neurology Associates, Cullman, AL, (9)Austin Health and Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia, (10)St Michael’s Hospital, University of Toronto, Toronto, ON, Canada, (11)Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain, (12)Cleveland Clinic, Cleveland, OH, (13)University Hospital San Carlos, Madrid, Spain, (14)Salford Royal NHS Foundation Trust, Salford, United Kingdom, (15)VU University Medical Center, Amsterdam, Netherlands, (16)Sanofi, Cambridge, MA, (17)University of British Columbia, Vancouver, BC, Canada |
| 2019 | DXT11 | Poster | Disease Modifying Therapy |
Improved Clinical, MRI Lesion, and Brain Volume Loss Outcomes With Alemtuzumab: 8-Year Follow-up of CARE-MS II Patients With Active RRMS (TOPAZ Study) |
Sibyl Wray, MD1, Raed Alroughani, MD2, Simon Broadley, MD3, Sara Eichau, MD, PhD4, Hans-Peter Hartung, MD5, Eva K Havrdova, MD, PhD6, Ho Jin Kim, MD7, Kunio Nakamura, PhD8, Carlos Navas, MD9, Carlo Pozzilli, MD10, Alex Rovira, MD11, Barry A Singer, MD12, Patrick Vermersch, PhD13, Luke Chung, MD, MPH14, Nadia Daizadeh, PhD14, Salman Afsar, MD14, Krzysztof W Selmaj, MD15 and on behalf of the CARE-MS II, CAMMS03409, and TOPAZ Investigators, (1)Neurology PC, Knoxville, TN, (2)Amiri Hospital, Sharq, Kuwait, (3)School of Medicine, Gold Coast Campus, Griffith University, Queensland, Australia, (4)Hospital Universitario Virgen Macarena, Seville, Spain, (5)Heinrich-Heine University, Dusseldorf, Germany, (6)First Medical Faculty, Charles University in Prague, Prague, Czech Republic, (7)Research Institute and Hospital of National Cancer Center, Goyang, Korea, Republic of (South), (8)Cleveland Clinic, Cleveland, OH, (9)Clinica Universitaria Colombia, Bogota, Colombia, (10)University of Rome, Rome, Italy, (11)Vall d’Hebron University Hospital, Barcelona, Spain, (12)MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, (13)University of Lille, Lille, France, (14)Sanofi, Cambridge, MA, (15)University of Warmia and Mazury, Olsztyn, Poland |
| 2019 | DXT12 | Poster | Disease Modifying Therapy |
Assessing the Effect of Teriflunomide on Unique Active Lesions in Patients Converting to Multiple Sclerosis in the Phase 3 TOPIC Study |
Alex Rovira, MD1, Young-Min Lim, MD2, Christine Lebrun-Frenay, MD, PhD3, Jerome De Seze, MD, PhD4, Richard Macdonell, MD5, Aaron E Miller, MD6, David KB Li, MD7, Deyanira Ramirez, MD8, Alex L Lublin, PhD9, Jeffery Chavin, MD9, Elizabeth M Poole, PhD9 and Anthony Traboulsee, MD10, (1)Vall d’Hebron University Hospital, Barcelona, Spain, (2)Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South), (3)Pasteur Hospital 2, Nice, France, (4)Clinical Investigation Center (CIC), INSERM 1434, CHU de Strasbourg, Strasbourg, France, (5)Department of Neurology, Austin Health, Heidelberg, Australia, (6)Icahn School of Medicine at Mount Sinai, New York, NY, (7)Department of Radiology, Faculty of Medicine, University of British Columbia, Vancouver, WA, Canada, (8)Collaborative Multiple Sclerosis Group of Central America and Spanish Caribbean Region, Santo Domingo, Dominican Republic, (9)Sanofi, Cambridge, MA, (10)Clinical Trials Research Group, University of British Columbia, Vancouver, WA, Canada |
| 2019 | DXT13 | Poster | Disease Modifying Therapy |
Post Hoc Analyses of Treatment Retention and Satisfaction in the Subgroup of Hispanic/Latino Patients from the PREFERMS Study |
Angel R Chinea Martinez, Dr1, Lilyana Amezcua, MD, MS2, Brett T Lund, Dr3, Xiangyi Meng, PhD4, Lesley Schofield, PhD4 and Nadia Tenenbaum, MD4, (1)San Juan MS Center, Caribbean Neurological Center, Guaynabo, PR, (2)Keck School of Medicine, University of Southern California, Los Angeles, CA, (3)Keck School of Medicine USC, University of Southern California, Los Angeles, CA, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ |
| 2019 | DXT14 | Poster | Disease Modifying Therapy |
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis |
Stephen L Hauser, MD1, Ludwig Kappos, MD2, Xavier Montalban, MD, PhD3,4, Richard Hughes, PhD5, John McNamara, BSc MSc CStat6, Ashish Pradhan, MD7, David Wormser, MSc, MPhil PhD5, Harold Koendgen, MD PhD5 and Jerry S Wolinsky, MD8, (1)University of California San Francisco, San Francisco, CA, (2)University Hospital Basel, University of Basel, Basel, Switzerland, (3)Division of Neurology, University of Toronto, Toronto, ON, Canada, (4)Vall d’Hebron University Hospital, Barcelona, Spain, (5)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (6)John McNamara Consulting Limited, Cambridge, United Kingdom, (7)Genentech, Inc., South San Francisco, CA, (8)McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX |
| 2019 | DXT15 | Poster | Disease Modifying Therapy |
Pregnancy Outcomes in Patients Treated with Ocrelizumab |
Sibyl Wray, MD1, Sandra Vukusic, MD, PhD2, Ludwig Kappos, MD3, Silvia Bader-Weder, MD4, Regine Buffels, MD4, Julie Napieralski, PhD4, Ashish Pradhan, MD5 and Stephen L Hauser, MD6, (1)Neurology PC, Knoxville, TN, (2)Service de Neurologie et Sclerose en Plaques, Fondation EDMUS pour la Sclerose en Plaques, Hopital Neurologique Pierre Wertheimer, Lyon, France, (3)University Hospital Basel, University of Basel, Basel, Switzerland, (4)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (5)Genentech, Inc., South San Francisco, CA, (6)University of California San Francisco, San Francisco, CA |
| 2019 | DXT16 | Poster | Disease Modifying Therapy |
Efficacy and Safety of Fingolimod Versus Glatiramer Acetate in Patients with Relapsing-Remitting Multiple Sclerosis in the Assess Study |
Bruce A C Cree, MD, PhD, MAS1, John Corboy, MD2, Barry A Singer, MD3, Edward J. Fox, MD, PhD4, Douglas L Arnold, MD5, Corey C Ford, MD, PhD6, Bianca Weinstock-Guttman, MD7, Amit Bar-Or, MD8, Susanne Mientus, PhD9, Daniel Sienkiewicz, PhD10, Ying Zhang, PhD10, Rajesh Karan, PhD9 and Nadia Tenenbaum, MD10, (1)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, (2)Department of Neurology, University of Colorado, Aurora, CO, (3)MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, (4)Central Texas Neurology Consultants, Round Rock, TX, (5)NeuroRx Research, Montreal, QC, Canada, (6)Department of Neurology, UNM Health Sciences Center, Albuquerque, NM, (7)Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, (8)Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, (9)Novartis Pharma AG, Basel, Switzerland, (10)Novartis Pharmaceuticals Corporation, East Hanover, NJ |
| 2019 | DXT17 | Poster | Disease Modifying Therapy |
Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) |
Edward J. Fox, MD, PhD1, Sibyl Wray, MD2, Richard Shubin, MD3, Koby Mok, PhD4, Sean Power, BA5, Jenna Bosco, BA5 and Michael Weiss, JD4, (1)Central Texas Neurology Consultants, Round Rock, TX, (2)Neurology PC, Knoxville, TN, (3)SC3 Research Group, Inc, Pasadena, CA, (4)Autoimmune, TG Therapeutics, Inc, New York, NY, (5)TG Therapeutics, New York, NY |
| 2019 | DXT18 | Poster | Disease Modifying Therapy |
Verismo: A Post-Marketing Safety Study to Determine the Incidence of All Malignancies and Breast Cancer in Patients with Multiple Sclerosis Treated with Ocrelizumab |
David Wormser, MSc, MPhil PhD1, Joanna Evershed, BSc2, Germano Ferreira, PharmD, MPH, PhD1, Daniela Stokmaier, MSc Pharm PhD1, Qing Wang, PhD1 and Tjalf Ziemssen, MD, PhD3, (1)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (2)Roche Products Ltd, Welwyn Garden City, United Kingdom, (3)Center of Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, Germany |
| 2019 | DXT19 | Poster | Disease Modifying Therapy |
Ensemble Baseline Results and Ensemble PLUS Study Design: An Investigation of Shorter Ocrelizumab Infusion Time in Patients with Relapsing-Remitting Multiple Sclerosis |
Robert Bermel, MD1, Bruno Brochet, MD2, Mark S Freedman, MSc, MD, FAAN, FRCPC3, Joep Killestein, MD, PhD4, Francesco Patti, MD, PhD5, Regine Buffels, MD6, Richard Hughes, PhD6, Lahar Mehta, PhD7, John McNamara, BSc MSc CStat6 and Hans-Peter Hartung, MD8, (1)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, (2)University of Bordeaux, Bordeaux, France, (3)THe University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada, (4)Department of Neurology, VU University Medical Center, Amsterdam, Netherlands, (5)GF Ingrassia, Department, Neuroscience Section, University of Catania, Catania, Italy, (6)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (7)Genentech, Inc., South San Francisco, CA, (8)Department of Neurology, UKD, Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany |
| 2019 | DXT20 | Poster | Disease Modifying Therapy |
Reduced Rate of Brain Atrophy after 5 Years of Ocrelizumab Treatment in Patients with Ppms from the Phase III Oratorio Trial |
Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath1, Hans-Peter Hartung, MD2, Stephen L Hauser, MD3, Ludwig Kappos, MD, PhD4, Xavier Montalban, MD, PhD5,6, Anthony Traboulsee, MD7, Jerry S Wolinsky, MD8, Karine Coutant, PhD9, Kalpesh Prajapati, PhD9, Fabian Model, PhD9, Lahar Mehta, PhD10 and Douglas L Arnold, MD11,12, (1)Queen Mary University of London, London, United Kingdom, (2)Department of Neurology, UKD, Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, (3)University of California San Francisco, San Francisco, CA, (4)University Hospital Basel, University of Basel, Basel, Switzerland, (5)Division of Neurology, University of Toronto, Toronto, ON, Canada, (6)Vall d’Hebron University Hospital, Barcelona, Spain, (7)University of British Columbia, Vancouver, BC, Canada, (8)McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, (9)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (10)Genentech, Inc., South San Francisco, CA, (11)NeuroRx Research, Montreal, QC, Canada, (12)McGill University, Montreal, QC, Canada |
| 2019 | DXT21 | Poster | Disease Modifying Therapy |
Sustained Improvement in Cognitive Processing Speed in Multiple Sclerosis Patients Completing 18 Months of Ozanimod Treatment: Results from the Phase 3 Sunbeam Trial |
John DeLuca, Ph.D.1, Jeffrey A Cohen, MD2, Bruce A C Cree, MD, PhD, MAS3, Yu Chen, PhD4, Danielle Harvey, MS4, James K Sheffield, MD, MBA, MS4, Diego Silva, MD, PhD4, Giancarlo Comi, MD5 and Ludwig Kappos, MD6, (1)Kessler Foundation, West Orange, NJ; Departments of Physical Medicine and Rehabilitation and Neurology, Rutgers – New Jersey Medical School, Newark, NJ, (2)Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, (3)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, (4)Celgene Corporation, Summit, NJ, (5)University Vita-Salute San Raffaele, Milan, Italy, (6)University Hospital Basel, University of Basel, Basel, Switzerland |
| 2019 | DXT22 | Poster | Disease Modifying Therapy |
Assessment of Low Baseline Heart Rate As Prognostic of Cardiac Events at First Dose for Patient Initiation of Fingolimod in Clinic and in the Gilenya at Home Program |
John Osborne, MD1, Brandon Brown, PharmD2, Xiangyi Meng, PhD2, Nina Jaitly, MD, MPH2, Wendy Su, PhD2 and Jamie L Weiss, PhD2, (1)State of the Heart Cardiology, Grapevine, TX, (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ |
| 2019 | DXT23 | Poster | Disease Modifying Therapy |
Effect of Subcutaneous Treatment with an Anti-CD20 Antibody on B-Cell Depletion in a Lipopolysaccharide-Induced Inflammatory Mouse Model |
Janet Dawson, PhD, Ismahane Touil, PhD, Anja Scheidegger, PhD, Melanie Vogelsanger, PhD, David Leppert, MD and Gisbert Weckbecker, MD, Novartis Pharma AG, Basel, Switzerland |
| 2019 | DXT24 | Poster | Disease Modifying Therapy |
Post Hoc Analyses of Clinical Outcomes in Patients with and without Migraine/Headache in the Pooled Freedoms, Freedoms II and Transforms Populations |
Mary A Willis, MD1, Devon Conway, MD2, Regina Berkovich, MD3, Xiangyi Meng, PhD4, Scott Kolodny, MD4, Andy Cheadle, PhD4 and Maria Melanson, MD4, (1)Mellen Center, Cleveland Clinic, Cleveland, OH, (2)Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH, (3)USC Medical Center, Los Angeles, CA, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ |
| 2019 | DXT25 | Poster | Disease Modifying Therapy |
Time to Initiation of Disease Modifying Therapy for Multiple Sclerosis in Southern Alberta Is Decreasing |
Jamie Greenfield, MPH1, Colleen Harris, MN, NP, MSCN, MSCS2, Courtney Chandler, MOA, CPhT2 and Luanne M Metz, MD, FRCPC1,2, (1)Clinical Neurosciences, University of Calgary, Calgary, AB, Canada, (2)MS Clinic, University of Calgary, Calgary, AB, Canada |
| 2019 | DXT26 | Poster | Disease Modifying Therapy |
Higher Rates of No Evidence of Disease Activity (NEDA) in Relapsing Multiple Sclerosis Patients Treated with Ozanimod Vs Interferon Beta-1a in the Phase 3 Radiance Trial |
Lawrence Steinman, MD1, Giancarlo Comi, MD2, Bruce A C Cree, MD, PhD, MAS3, Amit Bar-Or, MD4, Krzysztof W Selmaj, MD5, Douglas L Arnold, MD6, Hans-Peter Hartung, MD7, Xavier Montalban, MD, PhD8, Eva K Havrdova, MD, PhD9, James K Sheffield, MD, MBA, MS10, Vivian Huang, PhD10, Diego Silva, MD, PhD10, Ludwig Kappos, MD11 and Jeffrey A Cohen, MD12, (1)Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, (2)Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, (3)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, (4)Center for Neuroinflammation and Experimental Therapeutics, and Multiple Sclerosis Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (5)Center for Neurology, Lodz, Poland, (6)Montreal Neurological Institute and Hospital, Montreal, QC, Canada, (7)Department of Neurology, Medical Faculty, Heinrich-Heine University, Dusseldorf, Germany, (8)Division of Neurology, University of Toronto, Toronto, ON, Canada, (9)Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic, (10)Celgene Corporation, Summit, NJ, (11)University Hospital and University of Basel, Basel, Switzerland, (12)Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH |
| 2019 | DXT27 | Poster | Disease Modifying Therapy |
Efficacy and Safety of Teriflunomide in Patients of Different Ages: Analysis of Pooled Clinical Trials and Real-World Data |
Jiwon Oh, MD, PhD, FRCPC1, Sandra Vukusic, MD, PhD2, Klaus Tiel-Wilck, MD, for the NTD research group3, Mauro Zaffaroni, MD4, Stanley Cohan, MD, PhD5, Byoung Joon Kim, MD6, Jihad Said Inshasi, MD7, David Rog, MD8, Darren P Baker, PhD9, Yelena Pyatkevich, MD9, Maxneil Guce, MD9, Elizabeth M Poole, PhD9 and Keith Edwards, MD10, (1)Division of Neurology, University of Toronto, Toronto, ON, Canada, (2)University Hospital of Lyon, Bron, France, (3)Neurologisches Facharztezentrum Berlin, Berlin, Germany, (4)MS Centre, Gallarate Hospital, Gallarate, Italy, (5)Providence Brain and Spine Institute, Portland, OR, (6)Samsung Medical Centre, Seoul, Korea, Republic of (South), (7)Dubai Medical College, Dubai, United Arab Emirates, (8)Greater Manchester Neurosciences Centre, Salford, United Kingdom, (9)Sanofi, Cambridge, MA, (10)MS Center of Northeastern New York, Latham, NY |
| 2019 | DXT28 | Poster | Disease Modifying Therapy |
Remaining on Dimethyl Fumarate for 3 Months Is Associated with High Rates of Long-Term Treatment Continuation in the Clinical Setting |
Krupa Pandey, MD1, Kathryn Giles, MD, MSc, FRCPC2, Francois H Jacques, MD3, Sami Fam, PhD4, Yang Lei, PhD4, Catherine Miller, PharmD, MPH4 and Cynthia C Jones, PhD4, (1)Hackensack Meridian, Hackensack University Medical Center, Hackensack, NJ, (2)Cambridge Memorial Hospital, Cambridge, ON, Canada, (3)Clinique Neuro-Outaouais, Gatineau, QC, Canada, (4)Biogen, Cambridge, MA |